Abstract Number: 360 • 2019 ACR/ARP Annual Meeting
Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis
Background/Purpose: Prophylaxis of acute gout flares when commencing urate lowering therapy is recommended by international guidelines. Whether this is a cost-effective intervention is currently unknown.…Abstract Number: 1113 • 2019 ACR/ARP Annual Meeting
Improving Healthcare Quality and Reducing Cost via Online Interaction for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool
Background/Purpose: Without efficient primary medical care and follow-up system in China, patients can choose any hospital or doctor they like in seeking medical care. As…Abstract Number: 1174 • 2018 ACR/ARHP Annual Meeting
Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis
Background/Purpose: The cost-effectiveness of different biologic therapies is an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this…Abstract Number: 1757 • 2018 ACR/ARHP Annual Meeting
An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: To better understand the available economic evaluations in eosinophilic granulomatosis with polyangiitis (EGPA), a systematic literature review was undertaken. The primary objective of this…Abstract Number: 2183 • 2018 ACR/ARHP Annual Meeting
Access to Prescription Drugs in Canada: Results from an Online Survey
Background/Purpose: Prescription medications are an important treatment option for patients living with arthritis. However, patients may often not have access to certain medications they hear…Abstract Number: 2995 • 2018 ACR/ARHP Annual Meeting
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Background/Purpose: To quantify the healthcare expenditures associated with oral glucocorticoids-related-adverse events (OGCs-AEs), among patients in the US with giant cell arteritis (GCA) using claims data…Abstract Number: 2251 • 2017 ACR/ARHP Annual Meeting
Preferences for Physical Activity: A Discrete Choice Experiment in People with Chronic Knee Pain
Preferences For Physical Activity: A Discrete Choice Experiment In People With Chronic Knee Pain Background/Purpose: Understanding preferences for physical activity (PA) can help guide patient…Abstract Number: 2497 • 2017 ACR/ARHP Annual Meeting
The Role of Individual and Country-Level Socio-Economic Factors in Work Participation in Patients with Spondyloarthritis across 22 Countries Worldwide: Results from the Comospa Study
Background/Purpose: Spondyloarthritis (SpA) carries substantial financial costs, including direct costs (use of medical services and treatments) and indirect costs (loss of work productivity). While disease…Abstract Number: 133 • 2017 ACR/ARHP Annual Meeting
Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden
Background/Purpose: Healthcare and work-loss costs are markedly higher in RA patients than in the general population. The EuroQol 5-Dimensions (EQ-5D) instrument, commonly applied to measure…Abstract Number: 199 • 2017 ACR/ARHP Annual Meeting
Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study
Background/Purpose: Little is known about the healthcare costs of systemic lupus erythematosus (SLE) patients in the years leading up to SLE diagnosis. We estimated the…Abstract Number: 224 • 2017 ACR/ARHP Annual Meeting
Patterns of Methotrexate Use in African Countries with Low Versus Medium/High Human Development Index: Preliminary Results of Semi-Structured Interviews
Background/Purpose: Methotrexate (MTX) is standard therapy for rheumatoid arthritis (RA) and also used to treat other rheumatic diseases. Existing guidelines for RA treatment/ MTX use…Abstract Number: 414 • 2017 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…Abstract Number: 1052 • 2017 ACR/ARHP Annual Meeting
Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Background/Purpose: Results from cost-effectiveness analysis (CEAs) comparing treatment options for patients with rheumatoid arthritis (RA) who have an inadequate response to an initial tumor necrosis…Abstract Number: 1059 • 2017 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tai Chi Versus Physical Therapy for Knee Osteoarthritis
Background/Purpose: A single-blind randomized comparative effectiveness trial showed that Tai Chi yielded beneficial effects similar to those of a standard course of physical therapy in…Abstract Number: 1080 • 2017 ACR/ARHP Annual Meeting
Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver Satisfaction
Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver SatisfactionBackground/Purpose: Patient reported outcomes (PROs) are powerful tools that facilitate…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »